Research ArticleArticle
Knee Pain Predicts Subsequent Shoulder Pain and the Association Is Mediated by Leg Weakness: Longitudinal Observational Data from the Osteoarthritis Initiative
Laura L. Laslett, Petr Otahal, Elizabeth M.A. Hensor, Sarah R. Kingsbury and Philip G. Conaghan
The Journal of Rheumatology October 2016, jrheum.160001; DOI: https://doi.org/10.3899/jrheum.160001
Laura L. Laslett
From the Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. L.L. Laslett was funded by an Osteoarthritis Research International Young Investigator Scholarship while at the University of Leeds. She is also supported by an Arthritis Australia – Australian Rheumatology Association Heald Fellowship and a National Health and Medical Research Council Early Career Fellowship (Clinical Research Fellowship; GNT1070586). This study was supported by an Arthritis Research UK project grant (ref 20800), the Arthritis Research UK Experimental Osteoarthritis Treatment Centre (ref 20083), and the NIHR Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the US National Institutes of Health, a branch of the US Department of Health and Human Services and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use dataset, and does not necessarily reflect the opinions or views of the OAI investigators, the National Institutes of Health, or the private funding partners. L.L. Laslett, GDPH, PhD, Postdoctoral Research Fellow, Menzies Institute for Medical Research, University of Tasmania, and Visiting Scholar, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P. Otahal, BSc, GDipSc, Statistician, Menzies Institute for Medical Research, University of Tasmania; E.M. Hensor, PhD, Biostatistician, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; S.R. Kingsbury, PhD, Postdoctoral Research Fellow, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P.G. Conaghan, FRACP, FRCP, PhD, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds. Address correspondence to Professor P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: P.Conaghan@leeds.ac.uk. Accepted for publication July 7, 2016.
Petr Otahal
From the Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. L.L. Laslett was funded by an Osteoarthritis Research International Young Investigator Scholarship while at the University of Leeds. She is also supported by an Arthritis Australia – Australian Rheumatology Association Heald Fellowship and a National Health and Medical Research Council Early Career Fellowship (Clinical Research Fellowship; GNT1070586). This study was supported by an Arthritis Research UK project grant (ref 20800), the Arthritis Research UK Experimental Osteoarthritis Treatment Centre (ref 20083), and the NIHR Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the US National Institutes of Health, a branch of the US Department of Health and Human Services and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use dataset, and does not necessarily reflect the opinions or views of the OAI investigators, the National Institutes of Health, or the private funding partners. L.L. Laslett, GDPH, PhD, Postdoctoral Research Fellow, Menzies Institute for Medical Research, University of Tasmania, and Visiting Scholar, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P. Otahal, BSc, GDipSc, Statistician, Menzies Institute for Medical Research, University of Tasmania; E.M. Hensor, PhD, Biostatistician, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; S.R. Kingsbury, PhD, Postdoctoral Research Fellow, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P.G. Conaghan, FRACP, FRCP, PhD, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds. Address correspondence to Professor P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: P.Conaghan@leeds.ac.uk. Accepted for publication July 7, 2016.
Elizabeth M.A. Hensor
From the Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. L.L. Laslett was funded by an Osteoarthritis Research International Young Investigator Scholarship while at the University of Leeds. She is also supported by an Arthritis Australia – Australian Rheumatology Association Heald Fellowship and a National Health and Medical Research Council Early Career Fellowship (Clinical Research Fellowship; GNT1070586). This study was supported by an Arthritis Research UK project grant (ref 20800), the Arthritis Research UK Experimental Osteoarthritis Treatment Centre (ref 20083), and the NIHR Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the US National Institutes of Health, a branch of the US Department of Health and Human Services and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use dataset, and does not necessarily reflect the opinions or views of the OAI investigators, the National Institutes of Health, or the private funding partners. L.L. Laslett, GDPH, PhD, Postdoctoral Research Fellow, Menzies Institute for Medical Research, University of Tasmania, and Visiting Scholar, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P. Otahal, BSc, GDipSc, Statistician, Menzies Institute for Medical Research, University of Tasmania; E.M. Hensor, PhD, Biostatistician, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; S.R. Kingsbury, PhD, Postdoctoral Research Fellow, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P.G. Conaghan, FRACP, FRCP, PhD, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds. Address correspondence to Professor P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: P.Conaghan@leeds.ac.uk. Accepted for publication July 7, 2016.
Sarah R. Kingsbury
From the Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. L.L. Laslett was funded by an Osteoarthritis Research International Young Investigator Scholarship while at the University of Leeds. She is also supported by an Arthritis Australia – Australian Rheumatology Association Heald Fellowship and a National Health and Medical Research Council Early Career Fellowship (Clinical Research Fellowship; GNT1070586). This study was supported by an Arthritis Research UK project grant (ref 20800), the Arthritis Research UK Experimental Osteoarthritis Treatment Centre (ref 20083), and the NIHR Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the US National Institutes of Health, a branch of the US Department of Health and Human Services and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use dataset, and does not necessarily reflect the opinions or views of the OAI investigators, the National Institutes of Health, or the private funding partners. L.L. Laslett, GDPH, PhD, Postdoctoral Research Fellow, Menzies Institute for Medical Research, University of Tasmania, and Visiting Scholar, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P. Otahal, BSc, GDipSc, Statistician, Menzies Institute for Medical Research, University of Tasmania; E.M. Hensor, PhD, Biostatistician, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; S.R. Kingsbury, PhD, Postdoctoral Research Fellow, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P.G. Conaghan, FRACP, FRCP, PhD, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds. Address correspondence to Professor P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: P.Conaghan@leeds.ac.uk. Accepted for publication July 7, 2016.
Philip G. Conaghan
From the Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK. L.L. Laslett was funded by an Osteoarthritis Research International Young Investigator Scholarship while at the University of Leeds. She is also supported by an Arthritis Australia – Australian Rheumatology Association Heald Fellowship and a National Health and Medical Research Council Early Career Fellowship (Clinical Research Fellowship; GNT1070586). This study was supported by an Arthritis Research UK project grant (ref 20800), the Arthritis Research UK Experimental Osteoarthritis Treatment Centre (ref 20083), and the NIHR Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the US National Institutes of Health, a branch of the US Department of Health and Human Services and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use dataset, and does not necessarily reflect the opinions or views of the OAI investigators, the National Institutes of Health, or the private funding partners. L.L. Laslett, GDPH, PhD, Postdoctoral Research Fellow, Menzies Institute for Medical Research, University of Tasmania, and Visiting Scholar, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P. Otahal, BSc, GDipSc, Statistician, Menzies Institute for Medical Research, University of Tasmania; E.M. Hensor, PhD, Biostatistician, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; S.R. Kingsbury, PhD, Postdoctoral Research Fellow, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds; P.G. Conaghan, FRACP, FRCP, PhD, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds. Address correspondence to Professor P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. E-mail: P.Conaghan@leeds.ac.uk. Accepted for publication July 7, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Knee Pain Predicts Subsequent Shoulder Pain and the Association Is Mediated by Leg Weakness: Longitudinal Observational Data from the Osteoarthritis Initiative
Laura L. Laslett, Petr Otahal, Elizabeth M.A. Hensor, Sarah R. Kingsbury, Philip G. Conaghan
The Journal of Rheumatology Oct 2016, jrheum.160001; DOI: 10.3899/jrheum.160001
Knee Pain Predicts Subsequent Shoulder Pain and the Association Is Mediated by Leg Weakness: Longitudinal Observational Data from the Osteoarthritis Initiative
Laura L. Laslett, Petr Otahal, Elizabeth M.A. Hensor, Sarah R. Kingsbury, Philip G. Conaghan
The Journal of Rheumatology Oct 2016, jrheum.160001; DOI: 10.3899/jrheum.160001